From Uncertainty to Opportunity: Navigating IPAY 2028

Feature
Video

Sponsored

How the 2028 Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care

Omar Hafez, SVP of Market Access at Avalere Health, discusses the upcoming changes tied to the Initial Price Applicability Year (IPAY) 2028—the first year Medicare will include medical benefit drugs in its price negotiations. There are significant implications for therapeutic areas like oncology, immunology, and neurology, and this new pricing model could affect provider reimbursement and patient access. Hafez offers strategic insights for pharmaceutical manufacturers on how to prepare, including understanding the importance of real-world evidence and global pricing strategies.

Recent Videos
Related Content